Medicare Compliance & Reimbursement - 2010 Issue 22
In other news...
Subscribe or sign in to view the full article.
Article Overview
This article summarizes an OIG audit related to Medicare Part B claims for a chemotherapy drug and discusses why coding and billing practices were affected during the audited years. It is relevant for billers, coders, compliance staff, and practices that handle drug claims under Medicare Part B, especially those monitoring how payment edits and audit findings affect claims processing. The piece also references the transition to newer CMS claim-editing safeguards and the broader compliance context around drug unit reporting.
Why This Topic Matters
It helps readers understand how audit findings and billing transitions can expose claim-payment errors and why claim-editing controls matter for drug reporting under Medicare Part B.
What You Will Learn
- The general focus of a Medicare Part B audit involving a chemotherapy drug
- How historical billing changes can affect claims processing
- Why claim-editing safeguards are relevant to drug claim compliance
- What kinds of audit findings may be reported by the OIG
Who Should Read This
- Medical coders
- Billers
- Compliance staff
- Revenue cycle professionals
- Physician practice administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com